Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019
NCT07282197
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
Darolutamide (BAY 1841788)
Sponsor
Peking University First Hospital